Aura Biosciences, Inc.
Public company- Headquarters
- BOSTON, Massachusetts
- Industry
- Biotechnology
- Ticker
- AURA
- CIK
- 0001501796
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| COOSusan Abu-Absi, Ph.D. | Aug 11, 2026 | Appointed |
| CFOAnthony Gibney | Aug 11, 2026 | Departed |
| Senior Vice President, Finance, Treasurer and SecretaryAmy Elazzouzi | Aug 11, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- Eloxx Pharmaceuticals, Inc.
director appointed: Geno J. Germano
- Voyager Therapeutics, Inc.
president appointed: Robin Swartz
- TScan Therapeutics, Inc.
Director departs: Garry Nicholson
- Moderna, Inc.
COO appointed: Juan Andres
- Executive appointment
COO appointed: Susan Abu-Absi, Ph.D.
Susan Abu-Absi, Ph.D. was named Chief Operating Officer of Aura Biosciences, Inc., effective August 10, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 11, 2026Role: Chief Operating Officer
- Executive departure
CFO departs: Anthony Gibney
Anthony Gibney, Chief Financial and Business Officer of Aura Biosciences, Inc., departs the role, effective September 1, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 11, 2026Role: Chief Financial and Business Officer
- Executive appointment
Senior Vice President, Finance, Treasurer and Secretary appointed: Amy Elazzouzi
Amy Elazzouzi was named Senior Vice President, Finance, Treasurer and Secretary of Aura Biosciences, Inc., effective September 2, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 11, 2026Role: Senior Vice President, Finance, Treasurer and Secretary
Last verified Nov 8, 2026